SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus

NCT06144710 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG: SG301 SC Injection
DRUG: SG301 SC Placebo

Sponsor

Hangzhou Sumgen Biotech Co., Ltd.